These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 29900067)

  • 1. Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer.
    Zhou G; Noordam L; Sprengers D; Doukas M; Boor PPC; van Beek AA; Erkens R; Mancham S; Grünhagen D; Menon AG; Lange JF; Burger PJWA; Brandt A; Galjart B; Verhoef C; Kwekkeboom J; Bruno MJ
    Oncoimmunology; 2018; 7(7):e1448332. PubMed ID: 29900067
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy.
    Ho WW; Gomes-Santos IL; Aoki S; Datta M; Kawaguchi K; Talele NP; Roberge S; Ren J; Liu H; Chen IX; Andersson P; Chatterjee S; Kumar AS; Amoozgar Z; Zhang Q; Huang P; Ng MR; Chauhan VP; Xu L; Duda DG; Clark JW; Pittet MJ; Fukumura D; Jain RK
    Proc Natl Acad Sci U S A; 2021 Nov; 118(45):. PubMed ID: 34725151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer.
    Slovak RJ; Park HJ; Kamp WM; Ludwig JM; Kang I; Kim HS
    Sci Rep; 2021 Mar; 11(1):6956. PubMed ID: 33772035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GITR Ligation Improves Anti-PD1-Mediated Restoration of Human MMR-Proficient Colorectal Carcinoma Tumor-Derived T Cells.
    Rakké YS; Campos Carrascosa L; van Beek AA; de Ruiter V; van Gemerden RS; Doukas M; Doornebosch PG; Vermaas M; Ter Borg S; van der Harst E; Coene PPLO; Kliffen M; Grünhagen DJ; Verhoef C; IJzermans JNM; Kwekkeboom J; Sprengers D
    Cell Mol Gastroenterol Hepatol; 2023; 15(1):77-97. PubMed ID: 36155259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study.
    Jary M; Liu WW; Yan D; Bai I; Muranyi A; Colle E; Brocheriou I; Turpin A; Radosevic-Robin N; Bourgoin P; Penault-Llorca F; Cohen R; Vernerey D; André T; Borg C; Shanmugam K; Svrcek M
    Mol Oncol; 2022 Jun; 16(11):2260-2273. PubMed ID: 34954864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
    van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
    Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
    Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
    J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immuno-Contexture and Immune Checkpoint Molecule Expression in Mismatch Repair Proficient Colorectal Carcinoma.
    Giacomelli M; Monti M; Pezzola DC; Lonardi S; Bugatti M; Missale F; Cioncada R; Melocchi L; Giustini V; Villanacci V; Baronchelli C; Manenti S; Imberti L; Giurisato E; Vermi W
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell.
    Wang B; Li F; Guo L; Lu S; Ma J; Ma Y; Meng Y; Wang J; Zhou X; Fu W
    World J Surg Oncol; 2020 Aug; 18(1):196. PubMed ID: 32767974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of genes and cellular response factors related to immunotherapy response in mismatch repair-proficient colorectal cancer: a bioinformatics analysis.
    Xue W; Shi J
    J Gastrointest Oncol; 2022 Dec; 13(6):3038-3055. PubMed ID: 36636048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD11b
    Kudo-Saito C; Ogiwara Y; Imazeki H; Boku N; Uemura Y; Zhang R; Kawano-Nagatsuma A; Kojima M; Ochiai A
    Am J Cancer Res; 2021; 11(11):5428-5439. PubMed ID: 34873470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors.
    Pedroza-Gonzalez A; Zhou G; Vargas-Mendez E; Boor PP; Mancham S; Verhoef C; Polak WG; Grünhagen D; Pan Q; Janssen H; Garcia-Romo GS; Biermann K; Tjwa ET; IJzermans JN; Kwekkeboom J; Sprengers D
    Oncoimmunology; 2015 Jun; 4(6):e1008355. PubMed ID: 26155417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune cell infiltrates in peritoneal metastases from colorectal cancer.
    Sundström P; Hogg S; Quiding Järbrink M; Bexe Lindskog E
    Front Immunol; 2024; 15():1347900. PubMed ID: 38384469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial.
    Gögenur M; Balsevicius L; Bulut M; Colak N; Justesen TF; Fiehn AK; Jensen MB; Høst-Rasmussen K; Cappelen B; Gaggar S; Tajik A; Zahid JA; Bennedsen ALB; D'Ondes TDB; Raskov H; Sækmose SG; Hansen LB; Salanti A; Brix S; Gögenur I
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37172969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.
    Liu S; Kong P; Wang X; Yang L; Jiang C; He W; Quan Q; Huang J; Xie Q; Xia X; Zhang B; Xia L
    Oncol Lett; 2019 Feb; 17(2):2335-2343. PubMed ID: 30675299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of intra-tumoral CD8
    Sideras K; Galjart B; Vasaturo A; Pedroza-Gonzalez A; Biermann K; Mancham S; Nigg AL; Hansen BE; Stoop HA; Zhou G; Verhoef C; Sleijfer S; Sprengers D; Kwekkeboom J; Bruno MJ
    J Surg Oncol; 2018 Jul; 118(1):68-76. PubMed ID: 29878369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients.
    Frey DM; Droeser RA; Viehl CT; Zlobec I; Lugli A; Zingg U; Oertli D; Kettelhack C; Terracciano L; Tornillo L
    Int J Cancer; 2010 Jun; 126(11):2635-43. PubMed ID: 19856313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.